Levi Strauss & Co. Appoints Chris Callieri as Chief Supply Chain Officer
'We're excited to welcome Chris to LS&Co. at this pivotal moment in our evolution into a DTC-first denim lifestyle company," said Gass. "With a proven track record of delivering results at scale, he's the right leader to strengthen our end-to-end supply chain agility, drive innovation, and advance our sustainability goals — all while delivering exceptional value to our fans worldwide. "
Callieri brings more than 20 years of international supply chain experience in the retail and consumer goods industries. He joins LS&Co. from Victoria's Secret & Co., where he served as chief supply chain officer, leading a global team across multiple geographies and overseeing product development, sourcing, production, and distribution and logistics for various categories including intimates, apparel, accessories and beauty. Previously he was at Tory Burch, where he was pivotal in implementing systems like PLM, Merchandise Planning and SAP, and led the transformation of the supply chain. Chris has a long-standing commitment to sustainability and established Tory Burch's sustainability team and strategy.
Prior to Tory Burch, Callieri held senior roles at Adidas, including senior vice president, product operations, where he was responsible for materials development, product development, sourcing and logistics for Adidas Lifestyle Brands. Callieri's extensive experience also includes leadership roles at HRC Advisory and A.T. Kearney, where he led various transformation initiatives and developed strategies to improve supply chain responsiveness and product innovation for leading retailers.
'I'm thrilled to join LS&Co. at such an exciting time for the iconic Levi's® brand, a true category leader that thrives at the center of culture," Callieri said. "I look forward to working with the talented LS&Co. team to deliver strong performance, serve our fans around the world, and strengthen Levi's® position as the world's definitive denim lifestyle brand."
About Levi Strauss & Co.
Levi Strauss & Co. (LS&Co.) is one of the world's largest brand-name apparel companies and a global leader in jeanswear. The company designs and markets jeans, casual wear and related accessories for men, women and children under the Levi's®, Levi Strauss Signature™ and Beyond Yoga® brands. Its products are sold in approximately 120 countries worldwide through a combination of chain retailers, department stores, online sites, and a global footprint of approximately 3,400 retail stores and shop-in-shops. Levi Strauss & Co.'s reported 2024 net revenues were $6.4 billion. For more information, go to http://levistrauss.com, and for financial news and announcements go to http://investors.levistrauss.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Flex LNG - Key information relating to the cash distribution for the second quarter 2025
HAMILTON, Bermuda, Aug. 20, 2025 /PRNewswire/ -- Key information relating to the cash distribution to be paid by Flex LNG Ltd. (the "Company") for the second quarter 2025. The distribution will be made from the Company's Contributed Surplus Account. Please note that from May 28, 2024, the standard settlement cycle for transactions executed in securities traded on the New York Stock Exchange ("NYSE") will be shortened from T+2 to T+1 (of which T equals trading date), while the Oslo Stock Exchange ("OSE") will continue to settle its trades on a T+2 basis. As a result, there will be different dates between the two stock exchanges, as set out below. During these interim days, investors may be restricted to move shares between NYSE and OSE. NYSE shareholders: Distribution amount: $0.75Declared currency: USDLast day including right: September 4, 2025Ex-date: September 5, 2025Record date: September 5, 2025Payment date: September 18, 2025Date of approval: August 19, 2025 OSE shareholders with shares registered in Euronext Securities Oslo: Distribution amount: $0.75 Declared currency: USD to be distributed in NOKLast day including right: September 3, 2025 Ex-date: September 4, 2025Record date: September 5, 2025Payment date: September 23, 2025Date of approval: August 19, 2025 For further questions regarding the timing of payments, please contact your bank, broker, nominee, or other financial intermediary. For more info please contact: Knut Traaholt, Chief Financial Officer of Flex LNG Management AS Telephone: +47 23 11 40 00Email: IR@ About Flex LNG Flex LNG is a shipping company focused on the growing market for Liquefied Natural Gas (LNG). Our fleet consists of thirteen LNG carriers on the water and all of our vessels are state-of-the-art ships with the latest generation two-stroke propulsion (MEGI and X-DF). These modern ships offer significant improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. Flex LNG is listed on the New York Stock Exchange as well as Oslo Stock Exchange under the ticker FLNG. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This information was brought to you by Cision View original content: SOURCE Flex LNG Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
29 minutes ago
- Business Upturn
Lupin launches Bosentan Tablets for Oral Suspension in US with 180-day exclusivity
By Aditya Bhagchandani Published on August 20, 2025, 10:16 IST Shares of Lupin Ltd. will be in focus on Wednesday, August 20, after the company announced the launch of Bosentan Tablets for Oral Suspension, 32 mg, in the United States. The launch, made in partnership with NATCO Pharma, comes with the advantage of 180-day first-to-file generic exclusivity, a significant opportunity in the niche space of pulmonary arterial hypertension (PAH) treatment. The government filing confirmed that Lupin's alliance partner NATCO Pharma received U.S. FDA approval for its Abbreviated New Drug Application (ANDA). Bosentan is indicated for the treatment of PAH in pediatric patients aged three years and above with idiopathic or congenital PAH, aiming to improve pulmonary vascular resistance and exercise ability. The drug is bioequivalent to Actelion Pharmaceuticals' Tracleer® Tablets for Oral Suspension, which had estimated annual U.S. sales of around USD 10 million as of June 2025. Lupin, a major player in generics and specialty formulations, continues to strengthen its U.S. portfolio with this launch. The company has a strong footprint across therapy areas, including respiratory, cardiovascular, anti-diabetic, and women's health, and operates 15 manufacturing sites and seven research centers globally. With the exclusivity window, Lupin and NATCO are positioned to capture market share in the PAH treatment segment before competition intensifies. Disclaimer: This article is for informational purposes only and should not be considered investment advice. Please consult a financial advisor before making any investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Yahoo
an hour ago
- Yahoo
KeyBanc Raises Dycom Industries (DY) Price Target to $295 on Telecom Growth
Dycom Industries, Inc. (NYSE:DY) is one of the best Russell 2000 stocks to buy now. On July 16, KeyBanc Capital Markets increased its price target for Dycom stock to $295, up from $255. The firm maintained its 'Overweight' rating on Dycom's shares, citing the company's strong sector positioning and the expectation that telecom infrastructure investments will remain high in the years to come. Photo by Scott Blake on Unsplash Specifically, KeyBanc highlighted Dycom's position at the start of a multi-year telecom investment expansion. Dycom, the analysts stated, has made robust private investments in fiber. Add to that the ongoing federal and state-funded rural broadband programs, as well as aggressive data center-led fiber builds. KeyBanc expects these initiatives to drive elevated spending in the industry for several years. The analysts also noted Dycom's national reach and scale in wireline construction. They stated that this fact gives the company an advantage in competing for contracts and capturing incremental growth opportunities. In that regard, KeyBanc noted that Dycom, as a 'telecom pure-play trading at approximately 11.3x FY27 estimates,' does not have its longer-than-usual growth cycle fully reflected in its current valuation. Dycom Industries, Inc. (NYSE:DY) is a specialty contracting company. It provides engineering, construction, maintenance, and installation services for telecommunications and utility infrastructure. The company operates across the United States, serving major telecommunications providers, cable operators, and utility companies through a network of field offices staffed by over 15,000 employees. While we acknowledge the potential of DY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Energy Stocks to Buy For the Long Term and Top 10 Industrial Stocks to Buy Amid Easing Tariff Uncertainties. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
